Biomarkers and their potential functions in idiopathic pulmonary fibrosis

References

• Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–151.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12_Part_1):963–967.
   PubMed Web of Science ®Google Scholar
• Wesołowski S, Kuś J. [Clinical presentation and medical management in patients with idiopathic pulmonary fibrosis before diagnosis]. Pneumonologia I Alergologia Polska. 1999;67(1–2):38–44.
   PubMedGoogle Scholar
• Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–1952.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795–806.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018Sep1;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
   PubMedGoogle Scholar
• Guiot J, Moermans C, Henket M, et al. Blood biomarkers in idiopathic pulmonary fibrosis. Lung. 2017 Jun;195(3):273–280.
   PubMed Web of Science ®Google Scholar
• Bauer Y, White ES, de Bernard S, et al. MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017 Jan;3(1):1.
   Google Scholar
• Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res. 2012 Apr;159(4):218–227.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2012 Sep;18(5):441–446.
   PubMed Web of Science ®Google Scholar
• Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014 Nov 1;307(9):L681–91.
   PubMed Web of Science ®Google Scholar
• Smaragda O, Konstantinos K, Irene T, et al. Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr Med Chem. 2009;16(10):1214–1228.
   PubMed Web of Science ®Google Scholar
• António M, Beltr?o M, Oksana S, et al. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir Med. 2015 Aug;109(8):1063–1068.
   PubMed Web of Science ®Google Scholar
• Ulivi P, Casoni GL, Foschi G, et al. MMP-7 and fcDNA serum levels in early NSCLC and idiopathic interstitial pneumonia: preliminary study. Int J Mol Sci. 2013 Dec 11;14(12):24097–24112.
   PubMed Web of Science ®Google Scholar
• White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2016;194(10):1242.
   PubMed Web of Science ®Google Scholar
• Sokai A, Tanizawa K, Handa T, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res. 2017 Jul;3(3):3.
   Google Scholar
• Changjiang X, Wu N, Xue L, et al. Serum concentrations of krebs von den lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case–control study. BMC Pulm Med. 2017;17(1):144.
   PubMedGoogle Scholar
• Zhu C, Zhao YB, Kong LF, et al. [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases]. Zhonghua Jie He He Hu Xi Za Zhi. 2016 Feb;39(2):93–97.
   PubMedGoogle Scholar
• Hamai K, Iwamoto H, Ishikawa N, et al. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers. 2016;2016:4759040.
   PubMed Web of Science ®Google Scholar
• Bennett D, Salvini M, Fui A, et al. Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP. Inflammation. 2019;42(2):463–470.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Taniguchi H, Kondoh Y, et al. Serum KL-6 in fibrotic NSIP: correlations with physiologic and radiologic parameters. Respir Med. 2010;104(1):127–133.
   PubMed Web of Science ®Google Scholar
• Lanzarone N, Gentili F, Alonzi V, et al. Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features. Intern Emerg Med. 2020. Doi:10.1007/s11739-020-02281-8
   PubMed Web of Science ®Google Scholar
• Heinrich S, Hartl D, Griese M. Surfactant protein A–from genes to human lung diseases. Curr Med Chem. 2006;13(27):3239–3252.
   PubMed Web of Science ®Google Scholar
• Wang K, Ju Q, Cao J, et al. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Jun;96(23):e7083.
   PubMed Web of Science ®Google Scholar
• Saito Y, Azuma A, Matsuda K, et al. Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation. Immunopharmacol Immunotoxicol. 2016 Dec;38(6):464–471.
   PubMed Web of Science ®Google Scholar
• Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009 Apr 15;179(8):717–723.
   PubMed Web of Science ®Google Scholar
• Carre PC, Mortenson RL, King TE Jr., et al. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest. 1991 Dec;88(6):1802–1810.
   PubMed Web of Science ®Google Scholar
• Iii Joseph P, Lynch S, Theodore J, et al. Neutrophilic alveolitis in idiopathic pulmonary fibrosis: the role of interleukin-8. Amer Rev Respir Dis. 1992;145(6):1433.
   PubMedGoogle Scholar
• Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000;11(3):279–303.
   PubMedGoogle Scholar
• Desai B, Mattson J, Paintal H, et al. Differential expression of monocyte/macrophage- selective markers in human idiopathic pulmonary fibrosis. Exp Lung Res. 2011;37(4):227–238.
   PubMed Web of Science ®Google Scholar
• O’Regan A, Berman JS Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Path. 2010;81(6): 373–390
   Google Scholar
• Annie P, Kevin G, José C, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2005;2(9):e251.
   PubMed Web of Science ®Google Scholar
• Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14(5):329–341.
   PubMed Web of Science ®Google Scholar
• Holbourn KP, Acharya KR, Perbal B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci. 2008;33(10):461–473.
   PubMed Web of Science ®Google Scholar
• Guiot J, Bondue B, Henket M, et al. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC Pulm Med. 2016;16(1):86.
   PubMedGoogle Scholar
• Guiot J, Henket M, Corhay JL, et al. Sputum biomarkers in IPF: evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. Plos One. 2017;12(2):e0171344.
   PubMed Web of Science ®Google Scholar
• Pilewski JM, Liu L, Henry AC, et al. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol. 2005;166(2):399–407.
   PubMed Web of Science ®Google Scholar
• Shijubo N, Imai K, Aoki S, et al. Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis. Clin Exp Immunol. 1992;89(1):58–62.
   PubMed Web of Science ®Google Scholar
• Nortamo P, Li R, Renkonen R, et al. The expression of human intercellular adhesion molecule-2 is refractory to inflammatory cytokines. Eur J Immunol. 1991;21(10):2629–2632.
   PubMed Web of Science ®Google Scholar
• Shijubo N, Imai K, Shigehara K, et al. Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Clin Exp Immunol. 1994;95(1):156–161.
   PubMed Web of Science ®Google Scholar
• Tsoutsou PG, Gourgoulianis KI, Petinaki E, et al. ICAM-1, ICAM-2 and ICAM-3 in the sera of patients with idiopathic pulmonary fibrosis. Inflammation. 2004;28(6):359–364.
   PubMed Web of Science ®Google Scholar
• Okuda R, Matsushima H, Aoshiba K, et al. Soluble intercellular adhesion molecule-1 for stable and acute phases of idiopathic pulmonary fibrosis. SpringerPlus. 2015;4(1):657.
   PubMedGoogle Scholar
• Fernandez IE, Amarie OV, Mutze K, et al. Systematic phenotyping and correlation of biomarkers with lung function and histology in lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2016;310(10):L919–27.
   PubMed Web of Science ®Google Scholar
• Nakao A, Hasegawa Y, Tsuchiya Y, et al. Expression of cell adhesion molecules in the lungs of patients with idiopathic pulmonary fibrosis. Chest. 1995;108(1):233–239.
   PubMed Web of Science ®Google Scholar
• Diaz-Pina G, Ordonez-Razo RM, Montes E, et al. The role of ADAR1 and ADAR2 in the regulation of miRNA-21 in idiopathic pulmonary fibrosis. Lung. 2018 Aug;196(4):393–400.
   PubMed Web of Science ®Google Scholar
• Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733–1741.
   PubMed Web of Science ®Google Scholar
• Pattarayan D, Thimmulappa RK, Ravikumar V, et al. Diagnostic potential of extracellular microRNA in respiratory diseases. Clin Rev Allergy Immunol. 2018 Jun;54(3):480–492.
   PubMed Web of Science ®Google Scholar
• Liu B, Jiang T, Hu X, et al. Downregulation of microRNA30a in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis patients. Mol Med Rep. 2018 Dec;18(6):5799–5806.
   PubMed Web of Science ®Google Scholar
• Tsitoura E, Wells AU, Karagiannis K, et al. MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells. Oncotarget. 2016 Nov 15;7(46):74569–74581.
   PubMedGoogle Scholar
• Makiguchi T, Yamada M, Yoshioka Y, et al. Serum extracellular vesicular miR-21-5p is a predictor of the prognosis in idiopathic pulmonary fibrosis. Respir Res. 2016 Sep 5;17(1):110.
   PubMed Web of Science ®Google Scholar
• Li S, Geng J, Xu X, et al. miR-130b-3p modulates epithelial-mesenchymal crosstalk in lung fibrosis by targeting IGF-1. PLoS One. 2016;11(3):e0150418.
   PubMed Web of Science ®Google Scholar
• Ge L, Habiel DM, Hansbro PM, et al. miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways. JCI Insight. 2016 Dec 8;1(20):e90301.
   PubMed Web of Science ®Google Scholar
• Yang G, Yang L, Wang W, et al. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression. Gene. 2015 May 10;562(1):138–144.
   PubMed Web of Science ®Google Scholar
• Ji X, Wu B, Fan J, et al. The anti-fibrotic effects and mechanisms of microRNA-486-5p in pulmonary fibrosis. Sci Rep. 2015 Sep 15;5(1):14131.
   PubMedGoogle Scholar
• Fierro-Fernandez M, Busnadiego O, Sandoval P, et al. miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2. EMBO Rep. 2015 Oct;16(10):1358–1377.
   PubMed Web of Science ®Google Scholar
• Liang C, Li X, Zhang L, et al. The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis. Exp Mol Pathol. 2015 Oct;99(2):279–285.
   PubMed Web of Science ®Google Scholar
• Akihiko S, Kiminobu T, Tomohiro H, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3(3):00019–2016.
   Google Scholar
• Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006 Mar;11(2):164–168.
   PubMed Web of Science ®Google Scholar
• Sokai A, Tanizawa K, Handa T, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3(3):3.
   Google Scholar
• Ohnishi H, Miyamoto S, Kawase S, et al. Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis. BMC Pulm Med. 2014;14(1):129.
   PubMedGoogle Scholar
• Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009 Jun;135(6):1557–1563.
   PubMed Web of Science ®Google Scholar
• Greene KE, King TE Jr., Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002 Mar;19(3):439–446.
   PubMed Web of Science ®Google Scholar
• Nishikiori H, Chiba H, Ariki S, et al. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2014 Dec;8(14):196.
   Google Scholar
• Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5(12):946–955.
   PubMed Web of Science ®Google Scholar
• Doubková M, Karpíšek M, Mazoch J, et al. Prognostic significance of surfactant protein A, surfactant protein D, clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease. Sarcoidosis, Vasculitis, Diffuse Lung Dis. 2016;33(3):224–234.
   PubMed Web of Science ®Google Scholar
• O’Dwyer David N, Moore Bethany B. The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci. 2017;74(23):4305–4314.
   PubMed Web of Science ®Google Scholar
• Kenji I, Conway Simon J, Moore Bethany B, et al. Roles of periostin in respiratory disorders. Am J Respir Crit Care Med. 2016;193(9):949.
   PubMed Web of Science ®Google Scholar
• Ohta S, Okamoto M, Fujimoto K, et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PloS One. 2017;12(3):e0174547.
   PubMed Web of Science ®Google Scholar
• Korthagen NM, van Moorsel CH, Barlo NP, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med. 2011 Jan;105(1):106–113.
   PubMed Web of Science ®Google Scholar
• Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med. 2010 Aug;104(8):1204–1210.
   PubMed Web of Science ®Google Scholar
• Korthagen NM, van Moorsel CH, Zanen P, et al. Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias. Lung. 2014 Dec;192(6):975–980.
   PubMed Web of Science ®Google Scholar
• Kulkarni HS, Guzy RD, McEvoy C. YKL-40 in pediatric asthma, MUC5B promoter polymorphism in idiopathic pulmonary fibrosis, and esmolol in septic shock. Am J Respir Crit Care Med. 2014 May 1;189(9):1138–1140.
   PubMed Web of Science ®Google Scholar
• Maher TM. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Curr Opin Pulm Med. 2013 Sep;19(5):460–465.
   PubMed Web of Science ®Google Scholar
• Papiris SA, Tomos IP, Karakatsani A, et al. High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations. Cytokine. 2018 Feb;102:168–172.
   PubMed Web of Science ®Google Scholar
• Totani Y, Saitoh Y, Sakakibara H, et al. [Clinical characterization of interleukin-8 in patients with idiopathic pulmonary fibrosis]. Nihon Kokyuki Gakkai Zasshi. 2002 Nov;40(11):869–874.
   PubMedGoogle Scholar
• Ziegenhagen MW, Zabel P, Zissel G, et al. Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med. 1998;157(3):762–768.
   PubMed Web of Science ®Google Scholar
• Steve M, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87(9):858–870.
   PubMed Web of Science ®Google Scholar
• Andersson-Sjoland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol. 2008;40(10):2129–2140.
   PubMed Web of Science ®Google Scholar
• Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009 Apr 1;179(7):588–594.
   PubMed Web of Science ®Google Scholar
• Mads D, Mikkel R, Marja J. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett. 2007;581(19):3702–3710.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Tanaka Y, Namba T, et al. Heat shock protein 70 protects against bleomycin-induced pulmonary fibrosis in mice. Biochem Pharmacol. 2010 Sep 15;80(6):920–931.
   PubMed Web of Science ®Google Scholar
• Scheraga RG, Thompson C, Tulapurkar ME, et al. Activation of heat shock response augments fibroblast growth factor-1 expression in wounded lung epithelium: a possible mechanism for progressive lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2016;311(5):L941–L955.
   PubMed Web of Science ®Google Scholar
• Kahloon RA, Xue J, Bhargava A, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med. 2013 Apr 1;187(7):768–775.
   PubMed Web of Science ®Google Scholar
• Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012;2(7):a006502.
   PubMed Web of Science ®Google Scholar
• Vempati P, Popel AS, Mac Gabhann F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev. 2014;25(1):1–19.
   PubMed Web of Science ®Google Scholar
• Barratt SL, Flower VA, Pauling JD, et al. VEGF (vascular endothelial growth factor) and fibrotic lung disease. Int J Mol Sci. 2018;19(5):5.
   Web of Science ®Google Scholar
• Xu L, Bian W, Gu XH, et al. Differing expression of cytokines and tumor markers in combined pulmonary fibrosis and emphysema compared to emphysema and pulmonary fibrosis. COPD. 2017;14(2):245–250.
   PubMedGoogle Scholar
• McKeown S, Richter AG, O’Kane C, et al. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J. 2009;33(1):77–84.
   PubMed Web of Science ®Google Scholar
• Murray LA, Habiel DM, Hohmann M, et al. Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight. 2017;2(16):16.
   Web of Science ®Google Scholar
• SakaguchiS, SakaguchiN, AsanoM, etal. Immunologic self-tolerance maintained by activated Tcells expressing IL-2 receptor alpha-chains (CD25). Breakdown of asingle mechanism of self-tolerance causes various autoimmune diseases. JImmunol. 1995;155(3):1151–1164.
   PubMed Web of Science ®Google Scholar
• Shimon S, Tomoyuki Y, Takashi N, et al. Regulatory T cells and immune tolerance. Cell. 2008;133(5):0–787.
   Google Scholar
• Kotsianidis I, Nakou E, Bouchliou I, et al. Global impairment of CD4+CD25+FOXP3+regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(12):112–130.
   Google Scholar
• Koichiro K, Arata A, Kuniko M, et al. Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation. Respir Res. 2018;19(1):71.
   Google Scholar
• Matteo G, Andrea C, Roberta A, et al. Influence of condensation temperature on selected exhaled breath parameters. BMC Pulm Med. 2005;5(1):10.
   Google Scholar
• Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994;269(19):13725–13728.
   Google Scholar
• Gaston B, J M D, Loscalzo J, et al. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med. 1994;149(2):538–551.
   PubMed Web of Science ®Google Scholar
• Cameli P, Bergantini L, D’alessandro M, et al. Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis. Minerva Med. 2019 Nov.
   PubMed Web of Science ®Google Scholar
• Cameli P, Bergantini L, Salvini M, et al. Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis. Nitric Oxide. 2019;89:41–45.
   Google Scholar
• Ma J, Rubin BK, Voynow JA. Mucins, mucus, and goblet cells. Chest. 2018 Jul;154(1):169–176.
   PubMed Web of Science ®Google Scholar
• Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature. 2014 Jan 16;505(7483):412–416.
   PubMed Web of Science ®Google Scholar
• Oldham JM, Ma SF, Martinez FJ, et al. MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015 Dec 15;192(12):1475–1482.
   PubMed Web of Science ®Google Scholar
• Schwartz DA. Idiopathic pulmonary fibrosis is a genetic disease involving mucus and the peripheral airways. Ann Am Thorac Soc. 2018 Nov;15(Supplement_3):S192–s197.
   PubMedGoogle Scholar
• Schwartz DA. Idiopathic pulmonary fibrosis is a complex genetic disorder. Trans Am Clin Climatol Assoc. 2016;127:34–45.
   PubMedGoogle Scholar
• Mathai SK, Newton CA, Schwartz DA, et al. Pulmonary fibrosis in the era of stratified medicine. Thorax. 2016 Dec;71(12):1154–1160.
   PubMed Web of Science ®Google Scholar
• Renzoni E, Srihari V, Sestini P. Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings. F1000Prime Rep. 2014;6:69.
   PubMedGoogle Scholar
• Jiang H, Hu Y, Shang L, et al. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis. Int J Clin Exp Pathol. 2015;8(11):14953–14958.
   PubMed Web of Science ®Google Scholar
• Yang IV, Fingerlin TE, Evans CM, et al. MUC5B and idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2015 Nov;12 Suppl 2(Suppl 2):S193–9.
   PubMedGoogle Scholar
• Shay JW. Telomeres and aging. Curr Opin Cell Biol. 2018 Jun;52:1–7.
   PubMed Web of Science ®Google Scholar
• Liu YY, Shi Y, Liu Y, et al. Telomere shortening activates TGF-β/Smads signaling in lungs and enhances both lipopolysaccharide and bleomycin-induced pulmonary fibrosis. Acta Pharmacol Sin. 2018 Nov;39(11):1735–1745.
   PubMed Web of Science ®Google Scholar
• Snetselaar R, van Batenburg AA, van Oosterhout MFM, et al. Short telomere length in IPF lung associates with fibrotic lesions and predicts survival. PLoS One. 2017;12(12):e0189467.
   PubMed Web of Science ®Google Scholar
• Dressen A, Abbas AR, Cabanski C, et al. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respir Med. 2018 Aug;6(8):603–614.
   PubMed Web of Science ®Google Scholar
• Povedano JM, Martinez P, Flores JM, et al. Mice with pulmonary fibrosis driven by telomere dysfunction. Cell Rep. 2015 Jul 14;12(2):286–299.
   PubMed Web of Science ®Google Scholar
• Courtwright AM, El-Chemaly S. Telomeres in interstitial lung disease: the short and the long of it. Ann Am Thorac Soc. 2019 Feb;16(2):175–181.
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Maher TM. Respiratory microbiome in IPF: cause, effect, or biomarker? Lancet Respir Med. 2014 Jul;2(7):511–513.
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Willis-Owen SAG, Cox MJ, et al. Host-microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1640–1650.
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014 Oct 15;190(8):906–913.
   PubMed Web of Science ®Google Scholar
• O’Dwyer DN, Ashley SL, Gurczynski SJ, et al. Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med. 2019 May 1;199(9):1127–1138.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Saito A, Chiba H, et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis. Respir Res. 2018 Feb 27;19(1):34.
   PubMedGoogle Scholar
• Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014 Jul;2(7):548–556.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Molyneaux PL, Bernardinello N, et al. The role of the lung’s microbiome in the pathogenesis and progression of idiopathic pulmonary fibrosis. Int J Mol Sci. 2019;20(22):22.
   Web of Science ®Google Scholar
• Madan JC, Koestler DC, Stanton BA, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio. 2012;3(4):4.
   Google Scholar
• Liu B, Li R, Zhang J, et al. MicroRNA-708-3p as a potential therapeutic target via the ADAM17-GATA/STAT3 axis in idiopathic pulmonary fibrosis. Exp Mol Med. 2018 Mar 30;50(3):e465.
   PubMedGoogle Scholar
• Juarez MM, Chan AL, Norris AG, et al. Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. J Thorac Dis. 2015 Mar;7(3):499–519.
   PubMed Web of Science ®Google Scholar
• Sugino K, Nakamura Y, Muramatsu Y, et al. Analysis of blood neutrophil elastase, glutathione levels and pathological findings in postoperative acute exacerbation of idiopathic pulmonary fibrosis associated with lung cancer: two case reports. Mol Clin Oncol. 2016 Oct;5(4):402–406.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogura T, Miyazawa N, et al. Outcome of patients with acute exacerbation of idiopathic interstitial fibrosis (IPF) treated with sivelestat and the prognostic value of serum KL-6 and surfactant protein D. Nihon Kokyuki Gakkai Zasshi. 2007 Jun;45(6):455–459.
   PubMedGoogle Scholar
• Bando M, Ohno S, Hosono T, et al. Risk of acute exacerbation after video-assisted thoracoscopic lung biopsy for interstitial lung disease. J Bronchology Interv Pulmonol. 2009 Oct;16(4):229–235.
   PubMedGoogle Scholar
• Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Clin Respir J. 2018 Mar;12(3):1084–1092.
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med. 2014 Jul;108(7):1031–1039.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448–457.
   PubMed Web of Science ®Google Scholar
• Weng D, Chen XQ, Qiu H, et al. The role of infection in acute exacerbation of idiopathic pulmonary fibrosis. Mediators Inflamm. 2019;2019:5160694.
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Cox MJ, Wells AU, et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res. 2017 Feb 1;18(1):29.
   PubMed Web of Science ®Google Scholar
• Cao M, Swigris JJ, Wang X, et al. Plasma leptin is elevated in acute exacerbation of idiopathic pulmonary fibrosis. Mediators Inflamm. 2016;2016:6940480.
   PubMed Web of Science ®Google Scholar
• Min H, Fan S, Song S, et al. Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis. Diagn Pathol. 2016 Nov 23;11(1):135.
   PubMedGoogle Scholar